fda crackdown on compounded semaglutide Intensifies GLP-1 Compounding Hims to stop offering GLP-1
Description
At 1st Optimal, we see this all the time
Abbott NJ
Eli Lilly praised the ruling, claiming it would eliminate risky, unapproved knockoffs of the drugs
Lilly is also studying Zepbound for treatment of MASH (metabolic associated steatohepatitis) and has met its goal in a Phase 2 study
Post Log inSign up Post Bloomberg @business The boom in GLP-1 weight-loss drugs is boosting demand for protein supplements and driving a rally in the stock of Glanbia GLP-1 Craze Fuels Protein-Powder Maker Glanbias Share Rally From bloomberg.com 5:24 AM Jun 17, 202617.4KViews Don't miss what's happening People on X are the first to know
